MGMT-inhibitor in combination with TGF-βRI inhibitor or CDK 4/6 inhibitor increases temozolomide sensitivity in temozolomide-resistant glioblastoma cells.

Arabinda DasF C HendersonM AlshareefG B F PortoI KanginakudruL K InfingerW A VandergriftS M LindhorstA K VarmaS J PatelD Cachia

Published in: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico (2020)

This study establishes the groundwork for the development of a combinatorial pharmacologic approach by using either LY2385219 or LY2157299 inhibitor plus O6-Benzylguanine to augment temozolomide response in temozolomide-resistant GB cells.

Keyphrases

induced apoptosis
newly diagnosed
cell cycle arrest
signaling pathway
cell cycle
transforming growth factor